Zydus' Humira Biosimilar: The Story So Far In India

One dose of AbbVie's blockbuster biologic, Humira (adalimumab), in the US equals around six doses of Zydus Cadila's cut-price biosimilar version in terms of the cost of therapy and the Indian firm's product appears to have triggered interesting shifts both in treatment dynamics and the competitive landscape on the domestic market.

One dose of AbbVie's blockbuster biologic, Humira (adalimumab), in the US equals around six doses of Zydus Cadila's cut-price biosimilar version in terms of the cost of therapy and the Indian firm's product appears to have triggered interesting shifts both in treatment dynamics and the competitive landscape on the domestic market.

Zydus Cadila's Exemptia (adalimumab) costs INR11,000-14,000 ($163.4-208) per dose, a fraction of Humira's international price, estimated at around $1,000 per...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category